Biocompatible and bioabsorbable derivatized chitosan compositions

• US 9,925,310 B2
• Filed: 12/06/2016
• Issued: 03/27/2018
• Est. Priority Date: 03/14/2013
• Status: Active Grant

• Current Assignee: Tricol Biomedical, Inc. (Tricol International Group Ltd.)
• Original Assignee: Tricol Biomedical, Inc. (Tricol International Group Ltd.)
• Inventors: McGrath, Barbara, McCarthy, Simon, Kuhn, Sam, Wold, Alysha, Stolten, Michael, Bennett, Amanda
• Primary Examiner(s): Krishnan, Ganapathy
• Application Number:
  US15/371,010
• Publication Number:
  US 20170119934A1
• Time in Patent Office: 476 Days
• Field of Search: 514 23, 514 55, 514 77, 536 20, 536 553, 1061351
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 49/0008 Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 2400/04 Materials for stopping bleeding
• CPC Class Codes: A61L 27/20 Polysaccharides
• CPC Class Codes: A61L 27/26 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 27/58 Materials at least partially resorbable by the body
• CPC Class Codes: C08B 37/003 Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
• CPC Class Codes: C08L 2201/06 Biodegradable
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• CPC Class Codes: C08L 89/06 derived from leather or skin , e.g. gelatin
• CPC Class Codes: G01N 2333/545 IL-1
• CPC Class Codes: G01N 2400/28 Chitin, chitosan
• CPC Class Codes: G01N 33/5014 for testing toxicity
• CPC Class Codes: G01N 33/6869 Interleukin

Abstract

The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

Claims

1. A biocompatible, bioabsorbable deacetylated and reacetylated chitosan composition comprising a reacetylated chitosan having a molecular weight of about 90 kDa to about 170 kDa and a degree of N-deacetylation of between about 15% and 40%.

2. The composition of claim 1, wherein the composition is initially soluble in an aqueous solution below or at about pH 6.5.

3. The composition of claim 1, further comprising at least one of an acid content between about 0% (w/w) and 8% (w/w) and an active ingredient selected from the group consisting of calcium, albumin, fibrinogen, thrombin, factor VIIa, factor XIII, thromboxane A2, prostaglandin-2a, activated Protein C, vitronectin, chrondroitin sulfate, heparan sulfate, keratan sulfate, glucosamine, heparin, decorin, biglycan, testican, fibromodulin, lumican, versican, neurocan, aggrecan, perlecan, lysozyme, lysly oxidase, hexose oxidase, cholesterol oxidase, pyranose oxidase, choline oxidase, pyruvate oxidase, glycollate oxidase and/or aminoacid oxidase, hexose, cholesterol, pyranose, choline, pyruvate, glycollate, aminoacid, epidermal growth factor, platelet derived growth factor, Von Willebrand factor, tumor necrosis factor (TNF), transforming growth factor (TGF), insulin like growth factor, fibroblast growth factor (FGF), keratinocyte growth factor, vascular endothelial growth factor (VEGF), nerve growth factor, bone morphogenic protein (BMP), hepatoma derived growth factor (HDGF), interleukin, amphiregulin, retinoic acid, erythropoietin, mafenide acetate, silver sulfadiazine, silver nitrate, nanocrystalline silver, penicillin, ampicillin, methicillin, amoxicillin, clavamox, clavulanic acid, aztreonam, imipenem, streptomycin, kanamycin, tobramycin, gentamicin, vancomycin, clindamycin, lincomycin, erythromycin, polymyxin, bacitracin, amphotericin, nystatin, rifampicin, tetracycline, doxycycline, chloramphenicol, cefuroxime, cefradine, flucloxacillin, floxacillin, dicloxacillin, potassium clavulanate, clotrimazole, cyclopiroxalomine, terbidifine, ketoconazole, paclitaxel, docetaxel, imatinib, exemestane, tamoxifen, vemurafenib, ipilimumab, dacarbazine, interleukin-2, abiraterone, doxorubicin, 5-fluorouracil, tamoxifen, octreotide, sorafenib, resveratrol, ketamine, diclofenac, ibuprofen, paracetamol, codeine, oxycodone, hydrocodone, dihydromorphine, pethidine, buprenorphine, tramadol, venlafaxine, flupirtine, carbamazepine, gabapentin, pregabalin, lidocaine, autologous cell lines, stem cells, and combinations thereof.

4. The composition of claim 1, wherein the composition is cross-linked with at least one of gelatin and collagen.

5. The composition of claim 1, wherein the composition is capable of in vivo bioabsorption in less than one of about 90 days, about 60 days, about 30 days, and about 14 days.

6. The composition of claim 5, wherein the composition is at least 85% absorbed.

7. The composition of claim 1, wherein the composition has a degree of N-deacetylation between about 15% to 35%.

8. The composition of claim 1, wherein the composition comprises one of a freeze-dried sponge, a freeze-dried foam, a non-freeze-dried foam, an implant, a tissue scaffold, an implant device surface coating, a matrix, a fiber, a powder, a sheet, a film, a membrane, a nanofiber, a nanoparticle, and a hydrogel.

16. The composition of claim 1, wherein the composition has a degree of N-deacetylation between about 20% to 35%.

17. The composition of claim 1, wherein the composition has a degree of N-deacetylation between about 20% to 30%.

19. The composition of claim 1, further comprising an acid content between about 2% (w/w) and 8% (w/w).

9. A method of making a biocompatible, bioabsorbable chitosan composition comprising:

obtaining deacetylated chitosan;

producing reacetylated chitosan from the deacetylated chitosan having a degree of N-deacetylation of between 15% and 30%; and

resolubilizing the reacetylated chitosan to aqueous solution using carbonic acid.

10. The method of claim 9, further comprising selecting a deacetylated chitosan starting material having at least one of a degree of N-deacetylation of between about 75% to 100% and a purity of at least 99%.

11. The method of claim 9, further comprising reducing chitosan free amine functionality of a glucosamine C-2 nitrogen of the deacetylated chitosan with an electrophile.

12. The method of claim 9, further comprising combining the resolubilized reacetylated chitosan aqueous acidic solution and an aqueous gelatin solution.

13. The method of claim 9, further comprising cross-linking the chitosan with at least one of gelatin and collagen.

14. The method of claim 13, further comprising using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride to accomplish the cross-linking.

15. The method of claim 9, further comprising processing the chitosan into at least one of a freeze-dried sponge, a freeze-dried foam, a non-freeze-dried foam, an implant, a tissue scaffold, an implant device surface coating, a matrix, a fiber, a powder, a sheet, a film, a membrane, a nanofiber, a nanoparticle, and a hydrogel.

18. A biocompatible, bioabsorbable deacetylated and reacetylated chitosan composition comprising a reacetylated chitosan having a degree of N-deacetylation of between 15% and 30% and cross-linked with at least one of gelatin and collagen.

20. The composition of claim 18, further comprising an acid content between about 2% (w/w) and 8% (w/w).